Penn Medicine Abramson Cancer Center


 

Should We Treat High-Risk Smoldering Myeloma, Trials with Daratumumab In Frontline & General Approach for Newly Diagnosed Multiple Myeloma

559 views
February 24, 2020
Comments 0
Login to view comments. Click here to Login